The New Antibody Formats on the Block
More complex alternatives to monoclonal antibodies are demanding innovation from manufacturing and purification techniques.
Patrick Endres |
sponsored by Tosoh
Over the last fifteen years, monoclonal antibodies (mAbs) have dominated the market but, today, alternative antibody formats are coming through company pipelines, including mAb fragments, single-chain fragment antibodies, and modified antibodies, such as antibody drug conjugates (ADCs), engineered antibodies and bi-specific antibodies.
For conventional mAbs, pharma companies tended to have one platform process for all (or the majority of) products. But these same platforms are not optimized, or simply do not work, for other antibody formats. In short, manufacturers are facing significant challenges. For example, for mAbs production, protein A was used as capture chromatography resin in purification platforms, as it interacts with the FC part of a mAb, but what about antibody fragments? Well, fragments lack the FC part, so there is no interaction with protein A! To capture mAb fragments, there has been a need for innovative chromatographic media, such as Protein L, which binds to a different part. To that end, we launched our protein L resin (Toyopearl AF-rProtein L-650F) to help manufacturers adapt to newer antibody formats coming through pipelines.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine